Neos Therapeutics (NEOS) to Release Earnings on Monday
Neos Therapeutics (NASDAQ:NEOS) will issue its quarterly earnings data before the market opens on Monday, March 12th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.
Shares of Neos Therapeutics (NASDAQ:NEOS) opened at $8.95 on Friday. The stock has a market capitalization of $247.92, a P/E ratio of -2.62 and a beta of -0.20. The company has a current ratio of 2.42, a quick ratio of 2.14 and a debt-to-equity ratio of 4.01. Neos Therapeutics has a 12-month low of $6.30 and a 12-month high of $13.15.
An institutional investor recently raised its position in Neos Therapeutics stock. State Street Corp raised its holdings in shares of Neos Therapeutics Inc (NASDAQ:NEOS) by 29.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 316,855 shares of the company’s stock after buying an additional 72,395 shares during the quarter. State Street Corp owned about 1.16% of Neos Therapeutics worth $2,312,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 49.33% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Neos Therapeutics (NEOS) to Release Earnings on Monday” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/03/11/neos-therapeutics-neos-to-release-earnings-on-monday.html.
Neos Therapeutics Company Profile
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.